HCL Will Support Genmab for End-to-End IT Infrastructure Transformation
Modern, scalable Digital Foundation to support leading biotechnology company’s fast-paced global growth
HCL Technologies (HCL), a leading global technology company, has signed a multi-year contract with Genmab, an international biotechnology company, to support its IT infrastructure operations globally through a new future-proof Digital Foundation that spans Hybrid Cloud, Cybersecurity, Unified Service Management and Digital Workplace Services.
Copenhagen, Denmark-based Genmab is the creator of multiple antibody therapeutics, and its core purpose is to improve the lives of people with cancer. The company has locations in Utrecht, the Netherlands; Princeton, New Jersey, U.S.; and Tokyo. To support the company’s rapid growth, HCL’s centralized global service delivery model and innovative frameworks will enable Genmab to realize greater automation, improved cost transparency, enhanced operational efficiency and increased control.
For further details, please contact:
HCL Technologies
Meenakshi Benjwal, Americas
Dipshikha Bhattacharyya, EMEA
Devneeta Pahuja, India and APAC